A multi-center study focusing on Stage IV EGFR-mutant NSCLC patients treated with EGFR-TKI therapy reported that the nomogram integrating pretherapy CT-based signature improved the prediction accuracy of PFS significantly [20]. Here, EGFR is linked to non-small cell lung carcinoma.